International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
about
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative NeoplasmsThe diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersAdvances in the management of myelofibrosisJanus kinase inhibitors: jackpot or potluck?Ponatinib in refractory Philadelphia chromosome-positive leukemias.Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.Pomalidomide is active in the treatment of anemia associated with myelofibrosisLenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.A phase-2 trial of low-dose pomalidomide in myelofibrosis.Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosisRuxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.Emerging drugs for myelofibrosis.A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.Long-term results of prednisone treatment for the anemia of myelofibrosis.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialA phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisA phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisPomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesLong-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsOutcome of transplantation for myelofibrosis.MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisPhase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaJAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
P2860
Q21285040-CE10DE31-A993-4FBE-AB2B-4907898377B9Q24675681-213B7D65-BFF3-4B53-B73D-095D444DB6ADQ27008072-BA190028-D4D5-43C2-9ADE-7614CEF0A392Q27027230-3E4AB397-D3E5-4944-B358-E14CB4E4E5A2Q27851967-1F9D8388-796B-4109-B233-AE456DC215C6Q27853179-578DFE1C-9F1B-400B-9A9D-25334C13FFEEQ30244032-2EBE10F6-BACC-4F52-9026-4BE59C286AFEQ33385644-02534059-6245-4011-9FDC-178057F64E6EQ33386057-98E25CE8-EAE5-46A1-823B-0D2873C1A697Q33387514-7AFEC7A4-51A4-44D5-9BFE-3F722550B1A3Q33390073-C73FAB0D-55E1-4DC7-9666-BBCA695CD347Q33391880-E44D77D0-8C89-4CCE-9C0C-B4A968BB66AAQ33392689-EEFF61D9-C72D-4312-A9F0-B9A778CD982AQ33393587-0A8449CF-6CB5-46EE-8D5F-F709B9CECEE3Q33399980-8E5E9589-7897-4804-B81C-E0CC4DAA38A8Q33400570-A85DF10F-E66C-45DE-B447-15CCCE407E88Q33403735-08C68A6C-C0A7-4A6D-A4E2-38BC705E59E7Q33404574-9808F764-7C7D-4926-B797-4F56891A986DQ33405372-453E76C9-7C28-4765-9DD6-060ADF5FFA98Q33405714-0121364E-64DD-4D70-81A5-F793660F6014Q33406238-9A0A4790-482F-49C4-BCF0-3174BAEE51BCQ33406694-7A13F338-1E6E-4852-848F-5FD468E663B6Q33406990-E8E4F677-A3D4-4027-99BA-28055872BA53Q33421108-5505F76B-4B22-43C8-BDED-740FD00FEDD4Q33421596-A2973E28-54CE-4846-BA96-B20E39FCF4BCQ33422565-F8FAC494-C46F-4698-A374-0DE8292B72CAQ33432285-B048F616-2137-4FA6-8A3A-3987FF4BC26CQ33432406-1B9134EF-A10E-4124-A0DD-967FD0C1B8F7Q33432637-51E3E903-DC4E-4EDF-84BD-3D7ECB095151Q33434284-30665EFA-183A-4560-BF52-9629F697C8CDQ33435398-E237F0D7-5C20-4924-BE56-353EB2810556Q33436247-8EF0CEBB-7D90-4420-BE6B-E88179DDCE1AQ33437478-B5882E94-882D-4601-AEEB-0CC0D2EE7A78Q33843390-0CC28F4C-6426-4D89-8D5F-552F7F75A138Q34015474-43B2AB9E-2FDE-4481-A9FF-DA8FE58DEBE1Q34047897-E4D16302-DC7B-497A-A570-DDF8A13BCECEQ34146512-801FD4E2-B0DF-4DB4-94D3-D41A85AB18FDQ34150008-4C1AA577-6C2E-4C33-A9C8-45DE81423BBDQ34162867-2EE6DFD1-CD0D-43A7-9A98-92203BCF432DQ34165935-48E34153-AAC4-4044-9C00-60CFCB947E76
P2860
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
International Working Group (I ...... earch and Treatment (IWG-MRT).
@ast
International Working Group (I ...... earch and Treatment (IWG-MRT).
@en
type
label
International Working Group (I ...... earch and Treatment (IWG-MRT).
@ast
International Working Group (I ...... earch and Treatment (IWG-MRT).
@en
prefLabel
International Working Group (I ...... earch and Treatment (IWG-MRT).
@ast
International Working Group (I ...... earch and Treatment (IWG-MRT).
@en
P2093
P50
P1433
P1476
International Working Group (I ...... earch and Treatment (IWG-MRT).
@en
P2093
Brigitte Dupriez
D Gary Gilliland
Francisco Cervantes
Giovanni Barosi
Heinz Gisslinger
IWG for Myelofibrosis Research and Treatment (IWG-MRT)
James W Vardiman
John K Camoriano
John T Reilly
Juergen Thiele
P304
P356
10.1182/BLOOD-2006-03-009746
P407
P50
P577
2006-05-04T00:00:00Z